Avalon GloboCare Corp

Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. It operates through the following segments: Real Property Operating, Medical Related Consulting Services, and Development Services & Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. It operates through the Real Property Operating and Medical Related Consulting Services segments. The Real Property Operating segment includes property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related to rental properties. The Medical Related Consulting segment relates to labor and related benefits, travel expenses, and related to consulting services. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

Image Provided by Pexels With a compound annual growth rate (CAGR) of 34.2%, the global CAR-T cell therapy market is projected to hit $15.4 billion by 2028. This hypergrowth is largely driven by the incredible promise of CAR-T cell therapy as an effective, lasting way to fight cancer.

Avalon GloboCare Aims to Revolutionize Cell Therapy Market with a Faster, Safer CAR-T Treatment

PITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. (NASDAQ: AVCO) aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients within days instead of weeks.

UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare

NEW YORK, July 16, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Avalon GloboCare Corp. ("AVCO" or the "Company") (AVCO) relating to its proposed merger with Hebei Senlang Biotechnology Co. Ltd. The investigation focuses on whether Avalon GloboCare Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Avalon GloboCare Corp. - AVCO

Avalon GloboCare Corp (NASDAQ:AVCO) said its planned acquisition target, SenlangBio, has initiated a first-in-human clinical trial evaluating anti-EphA2 chimeric antigen receptor (CAR) T-cell therapy for recurrent glioblastoma.  Glioblastoma is the most common type of primary brain tumor -- a devastating and aggressive cancer with few treatment options.

Avalon GloboCare says its planned acquisition target SenlangBio starts first-in-human clinical trial for recurrent brain cancer

Trial evaluating EphA2-targeted CAR T-cell therapy in recurrent glioblastoma, an urgent and significant unmet medical need with no standard of care treatment option

Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer

Avalon GloboCare Corp (NASDAQ:AVCO) told shareholders that its acquisition of Hebei Senlang Biotechnology Co Ltd, the largest cell therapy company in northern China in terms of biomanufacturing, clinical development programs, and pre-clinical research, will enhance the company's capabilities in cell and gene therapy. The deal, which was announced June 13, 2021, will see Avalon enter into a share purchase agreement for an aggregate of 81 million shares of its common stock, valued at US$0.0001 per share.

Avalon GloboCare says SenlangBio will enhance its capabilities in cell and gene therapy

Previously Announced Execution of Definitive Agreement to Acquire SenlangBio

Avalon GloboCare CEO Provides Letter to Update Shareholders About Acquisition of SenlangBio

Cloudera

First Bancorp

Strongbridge Biopharma

Cimarex Energy

NEW YORK, June 15, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: First Bancorp (NASDAQ: FBNC)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Select Bancorp, Inc. Select Bancorp shareholders are expected to receive First Bancorp common stock in connection with the merger. If you are a First Bancorp shareholder, click here to learn more about your rights and options.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates FBNC, AVCO, XEC, CLDR, SBBP; Shareholders are Encouraged to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Avalon GloboCare Corp. (NASDAQ: AVCO) and Hebei Senlang Biotechnology Co. Ltd is fair to Avalon shareholders. In connection with the transaction, Avalon will issue 81 million shares of its common stock to acquire SenlangBio. Halper Sadeh encourages Avalon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (

Avalon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Avalon GloboCare Corp. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – AVCO

Avalon GloboCare Corp (NASDAQ: AVCO) has agreed to acquire Hebei Senlang Biotechnology, dubbed SenlangBio, a China-based cell therapy company, in an all-stock transaction. In connection with the transaction, Avalon will issue 81 million shares of its common stock.

Avalon GloboCare Adds Cell Therapy-Based Candidates For Cancer With SenlangBio Acquisition: Highlights

Avalon GloboCare Corp (NASDAQ:AVCO) has reached a definitive agreement to acquire Hebei Senlang Biotechnology Co Ltd, the largest cell therapy company in northern China in terms of biomanufacturing scale, breadth and depth of clinical development programs, and pre-clinical research.  SenlangBio's core technology platforms include chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR Gamma Delta T-cells (CAR-γδT), and armored tumor infiltrating lymphocytes (armTILs), the company said.

Avalon GloboCare inks definitive agreement to acquire Chinese cell therapy company Senlang Biotechnology

SenlangBio, a world-class cell therapy company, has developed a robust pipeline which includes 15 autologous and universal (“off-the-shelf”) CAR-T and CAR-γδ T cell therapy candidates targeting hematologic malignancies and solid tumors

Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction

FREEHOLD, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that it will be presenting at the Noble Capital Markets Investor Forum during the 16th Annual World Stem Cell Summit to be held virtually on June 14-18, 2021.

Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021

Avalon GloboCare Corp (NASDAQ:AVCO) has announced that its CEO David Jin will chair a session on “Hot Topics and Future Trends” at the 2021 World Stem Cell Summit, held virtually June 14-18, 2021.  The session will feature Avalon's two breakthrough technology platforms, S-layer nanotechnology and QTY code, in co-development with the Massachusetts Institute of Technology (MIT) and the University of Natural Resources and Life Sciences in Vienna (BOKU), respectively.

Avalon GloboCare says CEO to present S-layer nanotechnology, QTY code platforms at 2021 World Stem Cell Summit

FREEHOLD, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announces that the company's President and Chief Executive Officer, David Jin, M.D., Ph.D., will chair a session on the “Hot Topics and Future Trends” track at the 2021 Annual World Stem Cell Summit, which will take place virtually on June 14-18, 2021. The session will feature Avalon's two breakthrough technology platforms, S-layer nanotechnology and QTY code, in co-development with the Massachusetts Institute of Technology (MIT) and the University of Natural Resources and Life Sciences in Vienna (BOKU), respectively.

Avalon GloboCare To Present Its S-Layer and QTY Code Breakthrough Technology Platforms at The Prestigious Annual World Stem Cell Summit

Specializes in developing cell-based technologies and manages stem-cell banks and clinical laboratories Creates proprietary diagnostic and therapeutic products leveraging regenerative medicine and exosome technology Also helping in the fight against coronavirus (COVID-19) What Avalon GloboCare does: Avalon GloboCare Corp (NASDAQ:AVCO) specializes in developing cell-based technologies but is also involved in the management of stem-cell banks and clinical laboratories and the fight against coronavirus (COVID-19). Via its two platforms, Avalon Cell and Avalon Rehab, the company develops proprietary diagnostic and therapeutic products leveraging regenerative medicine and exosome technology.

Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus

Avalon GloboCare Corp (NASDAQ:AVCO) said it will collaborate with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the company's AVA-011 therapy and other RNA-based candidates. AVA-011 targets tumor antigens on cancer cells and is being developed for patients with relapsed/refractory B-cell lymphoblastic leukemia and non-Hodgkin's lymphoma ahead of the first human clinical trials.

Avalon GloboCare to partner with University of Pittsburgh Medical Center Hillman Cancer Center to develop therapies using FLASH-CAR tech

FREEHOLD, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announces entering into a collaboration agreement with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the clinical development and production of Avalon's next-generation, chimeric antigen receptor (CAR) therapies using FLASH CAR™ technology.

Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR™ Platform

Avalon GloboCare Corp (NASDAQ:AVCO) has said it is expanding its co-development research program with the Massachusetts Institute of Technology (MIT), involving the use of CRISPR-based genome editing and QTY protein design technology to potentially treat and prevent cancer metastasis – the spreading of cancer cells from the initial tumor site to surrounding tissues and other organs.   The company noted that its collaboration with MIT on the QTY code has already successfully generated a prototype device to soak up the excess chemokines and cytokines produced in the body that lead to a potentially fatal ‘cytokine storm,' which can occur in patients with coronavirus (COVID-19) and in cancer patients being treated with CAR T-cell therapy.

Avalon GloboCare expands its MIT co-development research program to fight cancer spread

FREEHOLD, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announces the expansion of its co-development research program with the Massachusetts Institute of Technology (MIT) to apply two leading technologies—CRISPR-based genome editing and QTY protein design—to potentially treat and prevent cancer metastasis.

Avalon GloboCare Expands Co-Development Program with MIT to Combat Cancer Metastasis

Avalon GloboCare seeking to tap the power of cells to fight cancer and coronavirus

FREEHOLD, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced an update on its partnership with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria. The collaboration brings together BOKU's S-layer nanotechnology with Avalon's expertise in biomanufacturing, cell therapy engineering, and clinical development.

Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Expand Partnership and Accelerate Development of S-Layer Based Vaccines and Cellular Therapeutics

Assure/Fastep® COVID-19 Point-of-Care Antibody Test is the First Test Granted FDA Emergency Use Authorization for Use with Fingerstick Blood Samples Assure/Fastep® COVID-19 Point-of-Care Antibody Test is the First Test Granted FDA Emergency Use Authorization for Use with Fingerstick Blood Samples

Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices

FREEHOLD, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a clinical update on its chimeric antigen receptor (CAR) T-cell therapy and allogeneic mesenchymal stromal cell (MSC) therapy programs following successful completion of its Phase I clinical trial of AVA-001, the Company’s leading CAR T-cell therapy candidate in development for patients with relapsed/refractory B-cell lymphoblastic leukemia (R/R B-ALL).

Avalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial

FREEHOLD, N.J., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that Dr. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon Globocare, will participate on a virtual panel, entitled, “New Approaches to COVID-19: Hidden Breakthroughs,” being held on Thursday, September 10, 2020 at 1:00 p.m. ET.

News for Avalon GloboCare Corp Stock (AVCO)